GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HeiLongJiang ZBD Pharmaceutical Co 603567.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

4.93

-1.60%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About HeiLongJiang ZBD Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603567.SS. It has been listed since 24 April 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥798.1m and a net loss of CN¥1.37bn. At that date it held total assets of CN¥10.63bn and shareholders' equity of CN¥6.28bn.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine. The company is headquartered in Harbin, Heilongjiang. The company went IPO on 2015-04-24. The firm's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The firm distributes its products under the brand named Zhenbaodao.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
24 Apr 2015
Employees
2,760
Website
zbdzy.com ↗

Leadership

Pay as last reported

  • Mr. Tonghua FangChairman of the Board, since 2011CN¥2.7m
  • Mr. Lei WangChief Financial OfficerCN¥694,200
  • Mr. Jiujiang YanGeneral Manager, Director, since 2019CN¥1.2m
  • Ms. Tianzhu LiDeputy General ManagerCN¥452,400
  • Ms. Xiuzhen LiDeputy General ManagerCN¥204,200
  • Ms. Zhongfang ZhangSecretary of the BoardCN¥290,500
  • Ms. Jing HuangStaff Elected Director
  • Mr. Yunqi ZhangDirectorCN¥80,000
  • Mr. Ruichao LinIndependent DirectorCN¥80,000
  • Mr. Zhiqun WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
32
Environment
28
Social
18
Governance
51
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HeiLongJiang ZBD Pharmaceutical produces 2,760 employees in Harbin, CN.
  • Zhenbaodao brand covers cardiovascular and anti-viral flu treatments.
  • Freeze-dried powder injections are a key product for fracture and osteoporosis care.

Weaknesses

  • Harbin headquarters limits market expansion in Western Europe.
  • 2015 IPO listing does not indicate recent financial growth.
  • Traditional Chinese medicine focus restricts global market reach.

Opportunities

  • Growing demand for cardiovascular treatments in China.
  • Expansion into anti-viral flu markets with Zhenbaodao brand.
  • New product development in immune enhancement segment.

Threats

  • Competition from domestic pharmaceutical firms in CN.
  • Regulatory changes in Chinese Health Care sector.
  • Over-reliance on traditional Chinese medicine products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.